DDInter416 DDInter1087
This drug is a broad spectrum antimycotic or antifungal agent. Clotrimazole's antimycotic properties were discovered in the late 1960s. Clotrimazole falls under the _imidazole_ category of _azole_ antifungals, possessing broad-spectrum antimycotic activity. It is available in various preparations, including creams, pessaries, and troche formulations (slowly dissolving tablets). As well as its antifungal activity, clotrimazole has become a drug of interest in treating several other diseases such as sickle cell disease, malaria and some cancers. The minimal side effect profile of this drug and its uncomplicated metabolic profile have led it to gain widespread acceptance for the treatment of mycotic outbreaks such as vaginal yeast infections as well as athlete's foot.
Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cutaneous effects, lipoatrophy, alopecia, and a severe failure to thrive; HGPS is uniformly fatal.[A224379, A224384, A224389, A224394, A224399] Mechanistically, HGPS is underpinned by a single heterozygous C-to-T mutation at position 1824 of the _LMNA_ gene, which results in the accumulation of an aberrant farnesylated form of lamin A called progerin in the inner nuclear membrane.[A224379, A224394] Lonafarnib is a farnesyl transferase (FTase) inhibitor (FTI), which reduces the farnesylation of numerous cellular proteins, including progerin; as progerin farnesylation is important for localization to the nuclear membrane, lonafarnib inhibits progerin accumulation and improves symptoms in HGPS patients.[A224379, A224414, A224419, L23414] Merck originally developed Lonafarnib and subsequently licensed it to Eiger Biopharmaceuticals Inc., which currently markets it under the trademark ZOKINVY™.[L23414, L23544] Lonafarnib was granted FDA approval on November 20, 2020, and is the first FDA-approved treatment for HGPS and other related progeroid laminopathies.[L23414, L23549]
Clotrimazole {u} (Compound) resembles {v} (Compound) Loperamide
Loperamide {u} may lead to a major life threatening interaction when taken with {v} Lonafarnib
Clotrimazole {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} (Compound) resembles {v} (Compound) Fexofenadine
Fexofenadine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lonafarnib
Clotrimazole {u} (Compound) resembles {v} (Compound) Loperamide
Loperamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tamoxifen
Tamoxifen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lonafarnib
Clotrimazole {u} (Compound) resembles {v} (Compound) Diphenidol
Diphenidol {u} (Compound) resembles {v} (Compound) Fexofenadine
Fexofenadine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lonafarnib
Clotrimazole {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sibutramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lonafarnib
Clotrimazole {u} (Compound) resembles {v} (Compound) Loperamide
Loperamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metronidazole
Metronidazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lonafarnib
Clotrimazole {u} (Compound) resembles {v} (Compound) Diphenidol
Diphenidol {u} (Compound) resembles {v} (Compound) Loperamide
Loperamide {u} may lead to a major life threatening interaction when taken with {v} Lonafarnib
Clotrimazole {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nitisinone
Nitisinone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lonafarnib
Clotrimazole {u} (Compound) resembles {v} (Compound) Loperamide
Loperamide {u} may lead to a major life threatening interaction when taken with {v} Clopidogrel
Clopidogrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lonafarnib
Clotrimazole {u} (Compound) resembles {v} (Compound) Sulfinpyrazone
Sulfinpyrazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lonafarnib
Clotrimazole (Compound) resembles Loperamide (Compound) and Loperamide may lead to a major life threatening interaction when taken with Lonafarnib
Clotrimazole (Compound) resembles Methadone (Compound) and Methadone (Compound) resembles Fexofenadine (Compound) and Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Clotrimazole (Compound) resembles Loperamide (Compound) and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Clotrimazole (Compound) resembles Diphenidol (Compound) and Diphenidol (Compound) resembles Fexofenadine (Compound) and Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Clotrimazole (Compound) resembles Methadone (Compound) and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Lonafarnib
Clotrimazole (Compound) resembles Loperamide (Compound) and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Clotrimazole (Compound) resembles Diphenidol (Compound) and Diphenidol (Compound) resembles Loperamide (Compound) and Loperamide may lead to a major life threatening interaction when taken with Lonafarnib
Clotrimazole (Compound) resembles Methadone (Compound) and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Clotrimazole (Compound) resembles Loperamide (Compound) and Loperamide may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Clotrimazole (Compound) resembles Sulfinpyrazone (Compound) and Sulfinpyrazone may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib